ALKS 3831
ALKS 3831 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
0
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Clinical Trials (7)
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
An Insulin Sensitivity Study in Healthy Subjects
A Phase 1 Safety Study in Adults With Schizophrenia
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7